Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3S3G

Crystal Structure of Human Aldose Reductase Complexed with Tolmetin

Summary for 3S3G
Entry DOI10.2210/pdb3s3g/pdb
DescriptorAldose reductase, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, Tolmetin, ... (4 entities in total)
Functional Keywordshuman aldose reductase, oxidoreductase
Biological sourceHomo sapiens (human)
Cellular locationCytoplasm: P15121
Total number of polymer chains1
Total formula weight39070.38
Authors
Zheng, X.,Chen, J.,Luo, H.,Hu, X. (deposition date: 2011-05-18, release date: 2012-04-04, Last modification date: 2023-11-01)
Primary citationZheng, X.,Zhang, L.,Zhai, J.,Chen, Y.,Luo, H.,Hu, X.
The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase.
Febs Lett., 586:55-59, 2012
Cited by
PubMed Abstract: Sulindac (SLD) exhibits both the highest inhibitory activity towards human aldose reductase (AR) among popular non-steroidal anti-inflammatory drugs and clear beneficial clinical effects on Type 2 diabetes. However, the molecular basis for these properties is unclear. Here, we report that SLD and its pharmacologically active/inactive metabolites, SLD sulfide and SLD sulfone, are equally effective as un-competitive inhibitors of AR in vitro. Crystallographic analysis reveals that π-π stacking favored by the distinct scaffold of SLDs is pivotal to their high AR inhibitory activities. These results also suggest that SLD sulfone could be a potent lead compound for AR inhibition in vivo.
PubMed: 22155003
DOI: 10.1016/j.febslet.2011.11.023
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.8 Å)
Structure validation

239149

건을2025-07-23부터공개중

PDB statisticsPDBj update infoContact PDBjnumon